An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044)

Thomas J. Herzog, John B. Liao, Karen Finkelstein, Lyndsay Willmott, Wei Duan, John W. Moroney, Joseph Buscema, Katie Campbell-Simms, Yong Yue, Susan Zweizig, Juan Liu, Xiaoyu Wang, Rong-Yu Zang, Rutie Yin, David M. O'Malley, Lingying Wu

Open source

DOI
10.1016/j.ygyno.2025.03.001
Published
2025-03
Container
Gynecologic Oncology
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.ygyno.2025.03.001,
  title = {An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044)},
  author = {Thomas J. Herzog and John B. Liao and Karen Finkelstein and Lyndsay Willmott and Wei Duan and John W. Moroney and Joseph Buscema and Katie Campbell-Simms and Yong Yue and Susan Zweizig and Juan Liu and Xiaoyu Wang and Rong-Yu Zang and Rutie Yin and David M. O'Malley and Lingying Wu},
  year = {2025},
  journal = {Gynecologic Oncology},
  doi = {10.1016/j.ygyno.2025.03.001},
  url = {https://doi.org/10.1016/j.ygyno.2025.03.001}
}

RIS

TY  - JOUR
TI  - An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044)
AU  - Thomas J. Herzog
AU  - John B. Liao
AU  - Karen Finkelstein
AU  - Lyndsay Willmott
AU  - Wei Duan
AU  - John W. Moroney
AU  - Joseph Buscema
AU  - Katie Campbell-Simms
AU  - Yong Yue
AU  - Susan Zweizig
AU  - Juan Liu
AU  - Xiaoyu Wang
AU  - Rong-Yu Zang
AU  - Rutie Yin
AU  - David M. O'Malley
AU  - Lingying Wu
PY  - 2025
JO  - Gynecologic Oncology
DO  - 10.1016/j.ygyno.2025.03.001
UR  - https://doi.org/10.1016/j.ygyno.2025.03.001
ER  - 

APA

Herzog, T. J., Liao, J. B., Finkelstein, K., Willmott, L., Duan, W., Moroney, J. W., Buscema, J., Campbell-Simms, K., Yue, Y., Zweizig, S., Liu, J., Wang, X., Zang, R., Yin, R., O'Malley, D. M., & Wu, L. (2025). An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044). Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2025.03.001

Source records